Author(s):
Pawar Kanchan, Sudrik Vaibhav, Datir Bhumika, Manchare Shital
Email(s):
pawark200435@gmail.com
DOI:
10.52711/2349-2988.2024.00037
Address:
Pawar Kanchan, Sudrik Vaibhav, Datir Bhumika, Manchare Shital
Department of Pharmacy, Shantiniketan College of Pharmacy, Dhotre (BK), Ahmednagar 414304.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2024
ABSTRACT:
This comprehensive review explores the current state of Respiratory Syncytial Virus (RSV) vaccination, emphasizing the developmental progress, potential benefits, challenges, and future directions. Drawing insights from scientific literature, ongoing clinical trials, and health organizations, the review crititically assesses the effectiveness and safety of RSV vaccine candidates. Key themes include the prevention of RSV infections, the reduction of illness severity, challenges in age-specific considerations, and the role of herd immunity. As several vaccine candidates approach regulatory approval, this review provides recommendations for targeted vaccination strategies, international collaboration, and robust surveillance systems. Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in infants and the second most frequent cause of death during the first year of life. This highly contagious seasonal virus is responsible for approximately 3 million hospitalizations and 120,000 deaths annually among children under the age of 5 years. Bronchiolitis is the most common severe manifestation; however, RSV infections are associated with an increased long-term risk for recurring wheezing and the development of asthma. There is an unmet need for new agents and a universal strategy to prevent RSV infections starting at the time of birth.
Cite this article:
Pawar Kanchan, Sudrik Vaibhav, Datir Bhumika, Manchare Shital. Comprehensive review of Respiratory Syncytial Virus (RSV) Vaccination: Progress, Challenges, and Future Direction. Research Journal of Science and Technology. 2024; 16(3):265-9. doi: 10.52711/2349-2988.2024.00037
Cite(Electronic):
Pawar Kanchan, Sudrik Vaibhav, Datir Bhumika, Manchare Shital. Comprehensive review of Respiratory Syncytial Virus (RSV) Vaccination: Progress, Challenges, and Future Direction. Research Journal of Science and Technology. 2024; 16(3):265-9. doi: 10.52711/2349-2988.2024.00037 Available on: https://rjstonline.com/AbstractView.aspx?PID=2024-16-3-13
REFERENCES:
1. Jha A, Jarvis H, Fraser C, Openshaw P. Respiratory Syncytial Virus. SARS, MERS and other Viral Lung Infections. 2016.
2. Nair H, Verma VR, Theodoratou E, Zgaga L, Huda T, Simões EA, Wright PF, Rudan I, Campbell H. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health. 2011 Dec; 11(3):1-6.
3. Jorquera PA, Anderson L, Tripp RA. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Review of Vaccines. 2016 Feb 1;15(2):173-87.
4. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries-a systematic review. International Journal for Equity in Health. 2018 Dec;17:1-1.
5. Mammas IN, Drysdale SB, Rath B, Theodoridou M, Papaioannou G, Papatheodoropoulou A, Koutsounaki E, Koutsaftiki C, Kozanidou E, Achtsidis V, Korovessi P. Update on current views and advances on RSV infection. International Journal of Molecular Medicine. 2020 Aug 1;46(2):509-20.
6. Read JF, Bosco A. Decoding susceptibility to respiratory viral infections and asthma inception in children. International Journal of Molecular Sciences. 2020 Sep 2;21(17):6372.
7. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries-a systematic review. International Journal for Equity in Health. 2018 Dec;17:1-1.
8. Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Frontiers in Immunology. 2019 Jul 25;10:1675.
9. Rosário-Ferreira N, Preto AJ, Melo R, Moreira IS, Brito RM. The central role of non-structural protein 1 (NS1) in influenza biology and infection. International Journal of Molecular Sciences. 2020 Feb 22; 21(4):1511.
10. Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Frontiers in Immunology. 2019 Jul 25;10:1675.
11. Artika IM, Dewantari AK, Wiyatno A. Molecular biology of coronaviruses: current knowledge. Heliyon. 2020 Aug 1; 6(8).
12. MacLellan KM. Structural studies on the respiratory syncytial virus nucleocapsid and the phosphoprotein. University of Glasgow (United Kingdom); 2005.
13. Latour S, Tanaka H, Demeure C, Mateo V, Rubio M, Brown EJ, Maliszewski C, Lindberg FP, Oldenborg A, Ullrich A, Delespesse G. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. The Journal of Immunology. 2001 Sep 1;167(5):2547-54.
14. Dolnik O, Gerresheim GK, Biedenkopf N. New perspectives on the biogenesis of viral inclusion bodies in negative-sense RNA virus infections. Cells. 2021 Jun 10;10(6):1460.
15. Stewart S. The Role of The Membrane Proximal Region of The M2 Cytoplasmic Tail in Virus Replication.
16. Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Frontiers in Immunology. 2019 Jul 25;10:1675.
17. Anderson LJ, Jadhao SJ, Paden CR, Tong S. Functional features of the respiratory syncytial virus G protein. Viruses. 2021 Jul 1;13(7):1214.
18. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development–a global agenda. Vaccine. 2016 Jun 3;34(26):2870-5.
19. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013 Apr 18;31:B209-15.
20. Lang PO, Aspinall R. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?. Expert Review of Vaccines. 2012 Feb 1;11(2):167-76.
21. Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines. 2020 Nov 11;8(4):672.
22. So AC, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, Russell B, Monroy-Iglesias M, Dolly S, Irshad S, Van Hemelrijck M. COVID-19 vaccine safety in cancer patients: a single centre experience. Cancers. 2021 Jul 16;13(14):3573.
23. Rioux M, Francis ME, Swan CL, Ge A, Kroeker A, Kelvin AA. The intersection of age and influenza severity: Utility of ferrets for dissecting the age-dependent immune responses and relevance to age-specific vaccine development. Viruses. 2021 Apr 15;13(4):678.
24. Baker RE, Mahmud AS, Wagner CE, Yang W, Pitzer VE, Viboud C, Vecchi GA, Metcalf CJ, Grenfell BT. Epidemic dynamics of respiratory syncytial virus in current and future climates. Nature Communications. 2019 Dec 4;10(1):5512.
25. Roberts JN, Graham BS, Karron RA, Munoz FM, Falsey AR, Anderson LJ, Marshall V, Kim S, Beeler JA. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine. 2016 Sep 22;34(41):4843-9.
26. Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EK, Sadoff J. Efficacy and safety of an Ad26. RSV. preF–RSV preF protein vaccine in older adults. New England Journal of Medicine. 2023 Feb 16;388(7):609-20.
27. Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP. Vaccination strategies against respiratory syncytial virus. Proceedings of the National Academy of Sciences. 2016 Nov 15;113(46):13239-44.
28. Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines. 2020 Nov 11;8(4):672.